Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

In studies on small animals and primates, Novavax's (NVAX) updated monovalent COVID-19 vaccine generates a robust immune response against the currently dominating Eris variant.

Novavax (NVAX) Updated COVID Jab Effective Against Eris Variant

Biotech company Novavax Inc (NYSE:NVAX) announced that its Covid vaccine is effective against the Eris variant.

Biotech Stock Bounces on Covid Vaccine Update

bluebird bio

Exact Sciences

Microsoft

Rivian Automotive

Roku

Super Micro Computer

The Nasdaq has taken a rather large hit in recent weeks, sinking about 7.5% between July 18 and Aug 17. Two of the main reasons for the decline are worries about U.S. inflation and the Chinese economy.

7 Very Oversold Nasdaq Stocks to Buy Right Now

AMC Entertainment

NVIDIA

LaZBoy

Nvidia shares NVDA, -2.77% rose 2%, ahead of its eagerly awaited results after the close. Cathie Wood's ARK Invest sold stock in the graphics chipmaker on Tuesday, according to a fund disclosure.

Nvidia stock rises ahead of results, AMC shares slump and other stocks on the move.

BioNTech SE

Moderna

Pfizer

Drugmakers like Pfizer and Moderna tamped down expectations. Now, cases are increasing.

Covid Hospitalizations Jump. So Could Vaccine Demand.

Novavax just announced promising news that could help lead to much-needed income later this year. The vaccine maker has expressed concerns about its ability to survive.

Why Are Shares of Novavax Soaring Today?

Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fall.

U.S. Govt to Urge Citizens to Get New COVID-19 Shots

Novavax's vaccine and new shots from Pfizer and Moderna are expected to roll out in the U.S. within weeks, pending potential approvals from the FDA.

Novavax says new Covid vaccine was effective against Eris variant in animal trials

Novavax (NASDAQ: NVAX ) stock led the surge of Covid-19 vaccine stocks, offering an updated vaccine it says is effective against new variants. The company said its new protein-based vaccine generated an immune response against the EG.5 subvariant, nicknamed “Eris,” that is increasing illness in the U.S. Novavax stock rose 13% and another 2.5% overnight.

Novavax (NVAX) Stock Is Getting Ready to Rally Again

Novavax Inc. NVAX, +13.03% said Tuesday that its updated COVID-19 vaccine has shown promise against newer strains of the virus. In small animal and non-human primate studies, the protein-based shot developed for this fall's vaccinations induced neutralizing antibody responses to the EG.5.1 variant–nicknamed “Eris,”–and the XBB.1.16.6 variant, the company said in a release.

Novavax says updated COVID vaccine effective against Eris, other new variants

Novavax Inc said on Tuesday its updated protein-based COVID-19 vaccine generated neutralizing antibody responses to the "Eris" subvariant in preclinical studies.

Novavax's updated COVID vaccine shows response against 'Eris' variant

Novavax's 2023-2024 season COVID vaccine candidate induced neutralizing responses to emerging subvariants EG.5.1 and XBB.1.16.6 in addition to XBB.1.5, XBB.1.16 and XBB.2.3 Upon regulatory approval, Novavax's COVID vaccine would be the only protein-based non-mRNA vaccine option available in key markets for the fall season GAITHERSBURG, Md. , Aug. 22, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that its updated protein-based XBB COVID vaccine candidate induced neutralizing antibody responses to the EG.5.1 and XBB.1.16.6 subvariants in small animal and non-human primate studies.

Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6

Last week, Moderna and BioNTech partner Pfizer said their new COVID vaccines work against the current dominant strain of omicron growing across the U.S. Today, the Biden administration announced a campaign for citizens to get the new boosters this fall.

Why Moderna, BioNTech SE, and Novavax Surged Today

One of the stock subgroups that's gaining significant attention in today's market is that of Covid-19 vaccine makers. Among today's biggest winners is beaten-down Novavax (NASDAQ: NVAX ).

Why Is Novavax (NVAX) Stock Up 15% Today?

Novavax, Moderna, Pfizer and its partner BioNTech are slated to roll out new shots designed to target the omicron subvariant XBB.1.5 this fall.

Covid vaccine stocks jump as new variants emerge ahead of fall shot rollout

The drugmakers designed their updated coronavirus shots to target the omicron subvariant XBB.1.5, which is slowly declining nationwide.

New Covid vaccines from Pfizer, Moderna and Novavax will likely protect against Eris variant

Novavax posted a surprising profit last quarter as revenue more than doubled. However, the COVID-vaccine maker might not generate much revenue next quarter.

Novavax Posted a Profit in Q2. Here's Why It Doesn't Matter

BioXcel Therapeutics

MannKind

Investors who've dipped their toe into the waters of biotech stocks know that the chances of these stocks crashing and burning is certainly higher than with most sectors. Failure is incredibly common for firms that engage in the development of pharmaceuticals.

3 Biotech Stocks to Sell in August Before They Crash and Burn

Three US pharmaceutical companies, Pfizer Inc (NYSE:PFE), Moderna Therapeutics Inc (NASDAQ:MRNA), and Novavax Inc, are gearing up to release updated Covid-19 vaccines this autumn. The new jabs are designed to combat recent strains, although not specifically the newly identified Eris variant.

Pfizer, Moderna and Novavax developing jab to combat new Covid strain

SAGE Therapeutics

Novavax's prospects in the coronavirus vaccine market look dim. Sage Therapeutics' recent regulatory news was a major blow to its prospects.

2 Beaten-Down Stocks That Still Aren't Worth Buying

A coronavirus subvariant is starting to garner more headlines, leading to greater concern about a surge. The biotech developed one of the three COVID vaccines currently authorized for use in this country.

Why Novavax Stock Blasted 8% Higher Today

Carvana

Mullen Automotive

Investing in growth stocks can be risky, especially for those migrating into new markets or turnaround ventures. Personally, I've experienced losses from such endeavors.

Danger! These 3 Growth Stocks Are a Definite No-Go for Investors.

Healthcare continues to lag in the broader market. Year to date, the Standards and Practices (S&P) 500 Health Care index is down 2% versus a 17% gain in the benchmark S&P 500 index.

3 Healthcare Stocks to Sell in August Before They Crash and Burn

Novavax (NVAX) reports better-than-expected Q2 earnings results, as earnings and revenues beat estimates. Shares drop due to lowered 2023 product sales guidance.

Novavax (NVAX) Q2 Earnings Beat, Stock Down 4% on '23 Sales Cut

It's not the only vaccine producer struggling to get by, but Novavax looked terminal earlier this year by its own admission.

News for Novavax Stock (NVAX)